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Abstract
An increased function in the mesolimbic dopaminergic system has been extensively associated with the
rewarding effects of both natural stimuli and drugs of abuse. Thus, dopamine receptor blockers, such as neuro-
leptic drugs, can be proposed as candidates for potential therapeutic approaches to treat drug dependence.
Notwithstanding, this therapeutic potential of neuroleptics critically depends on a selective action on the speciﬁc
mechanisms related to the development of addiction. We compared the effects of different doses of haloperidol,
ziprasidone and aripiprazole (ﬁrst-, second- and third-generation neuroleptics, respectively) on spontaneous
locomotor activity of mice in a novel environment, hyperlocomotion induced by acute cocaine administration
and cocaine-induced locomotor sensitization by a two-injection protocol. Whereas high doses of haloperidol
abolished the three behavioural paradigms without selectivity, low doses of ziprasidone selectively abolished
the development of the behavioural sensitization phenomenon. Finally, low doses of aripiprazole inhibited
acute cocaine-induced hyperlocomotion and behavioural sensitization without modifying spontaneous
locomotor activity. Thus, aripiprazole at lower doses was the most selective antipsychotic drug concerning the
inhibition of the development of behavioural sensitization to cocaine. Because locomotor sensitization in rodents
has been proposed to share plastic mechanisms with drug addiction in humans, our data provide relevant
suggestions to the clinical practice.
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Introduction
Most common drugs of abuse increase dopamine levels
in the mesoaccumbens dopaminergic system, which
modulates both their rewarding and psychomotor arousal
effects (Wise and Bozarth, 1987; Alcaro et al., 2007).
Therefore, dopaminergic drugs play an important role
in the efforts to develop pharmacological therapies for
the treatment of addiction. Based on pre-clinical studies,
dopamine agonists and antagonists have been proposed
as either drug substitutes, maintenance drugs or cocaine
antagonists (Mendelson and Mello, 1996; Karila et al.,
2008). Dopamine agonists, medications that directly
stimulate dopamine receptors or increase the levels of
synaptic dopamine, have a mechanism of action similar
to stimulants, although they do not necessarily have
the same activating effects on behaviour (Mariani and
Levin, 2012). Within this context, agonist replacement
therapy uses a drug from the same pharmacological fam-
ily as the abused drug to suppress withdrawal and drug
craving (Grabowski et al., 2004). This therapeutic ap-
proach has been showing as a promising treatment for co-
caine dependence (Mendelson and Mello, 1996; Karila
et al., 2008). However, most of these drugs are controlled
substances with inherent risks of misuse and diversion,
and their use in patients with substance use disorders is
complex.
Regarding dopaminergic antagonists, although anti-
psychotics have an elevated therapeutic potential for
the treatment of drug dependence, their use can lead to
plastic alterations in dopaminergic systems that can in-
crease addictive behaviour. Several studies have demon-
strated that chronic treatment with conventional
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neuroleptics such as haloperidol results in post-synaptic
dopamine D2 receptor proliferation (Burt et al., 1977;
Prosser et al., 1988; Vital et al., 1998), a phenomenon
known as dopaminergic supersensitivity because it
leads to an increased responsiveness to dopaminergic
agonists (Gianutsos et al., 1974; Frussa-Filho and
Palermo-Neto, 1990; Waddington and Gamble, 1980;
Chinen and Frussa-Filho, 1999; Andersen et al., 2005).
Within this context, neuroleptic-induced mesolimbic
dopaminergic supersensitivity would enhance the effects
of all drugs with the potential for abuse because, as men-
tioned above, all drugs of abuse increase dopamine re-
lease in the mesoaccumbens system. Indeed, the high
lifetime prevalence of substance abuse disorders observed
among schizophrenics has been proposed to be related to
the dopaminergic supersensitivity occurring in the meso-
limbic system in neuroleptic-treated patients (LeDuc and
Mittleman, 1995; Kosten et al., 1996; Fukushiro et al.,
2007, 2008).
Although chronic treatment with conventional neuro-
leptics has been related to the development of dopa-
minergic supersensitivity, newer atypical neuroleptics
do not appear to induce the supersensitivity phenomenon
(Rupniak et al., 1985; Fukushiro et al., 2007, 2008;
Carvalho et al., 2009). For example, ziprasidone – a
second-generation antipsychotic drug that has high afﬁ-
nity for serotonin (5-HT) receptors, including 5-HT2A,
5-HT2C, 5-HT1A and 5-HT1B/1D, as well as dopamine D2
receptors (Schmidt et al., 2001) – and aripiprazole – a
third-generation neuroleptic that appears to act as a par-
tial agonist at dopamine D2 and serotonin 5-HT1A recep-
tors as well as an antagonist at the 5-HT2A receptor
(Burris et al., 2002; Mamo et al., 2007) – are two of the
newer atypical antipsychotics that do not appear to result
in dopaminergic supersensitivity after repeated treatment
(Tadokoro et al., 2001; Fukushiro et al., 2007, 2008).
Apart from not producing mesolimbic dopaminergic
supersensitivity after chronic treatment, a potential anti-
craving neuroleptic agent must present selectivity to the
plastic mesolimbic neuronal alterations that contribute
to the development of drug dependence. Mesolimbic
dopaminergic neurotransmission also plays a fundament-
al role in natural rewards such as sex (Becker, 2009), ma-
ternal behaviour (Silva et al., 2003) and novelty (Bardo
et al., 1996). As a consequence, non-selective blockade
of mesolimbic dopaminergic receptors could lead to a
marked impairment of spontaneous behaviour. If a neuro-
leptic agent non-selectively blocks the neuronal mech-
anisms related to both the acute rewarding effects of
drugs of abuse and the development of drug dependence,
addictive patients will be at the risk of auto-administering
overdoses as well as presenting poor adherence to neuro-
leptic treatment.
In rodents, locomotor stimulation has been extensively
related to increased dopaminergic neurotransmission
in the mesoaccumbens system (Kelly et al., 1975; Delfs
et al., 1990). As a consequence, both novelty exposure
and acute administration of most common drugs
of abuse stimulate locomotor activity in rats and mice
(Frussa-Filho and Palermo-Neto, 1991; Frussa-Filho
et al., 1996; Quadros et al., 2002; Wuo-Silva et al., 2011).
Importantly, while there is tolerance to many of the ef-
fects of repeated drug treatments, the psychomotor and
positive reinforcing effects of cocaine and other drugs of
abuse often become progressively greater with repeated
administration (Robinson and Berridge, 1993, 2001; De
Vries et al., 1998). This phenomenon, called behavioural
sensitization, has been suggested to be useful for study-
ing the mechanisms underlying dopaminergic mesoac-
cumbens plasticity (Henry and White, 1991; Kalivas and
Stewart, 1991; Wolf et al., 1994), which appears to share
neuronal mechanisms with drug craving in humans
(Robinson and Berridge, 1993). Remarkably, it has been
demonstrated that it is unnecessary to repeatedly ad-
minister drugs of abuse for long periods of time to pro-
duce behavioural sensitization. Indeed, a single injection
of cocaine (Valjent et al., 2010), amphetamine (Frussa-
Filho et al., 2004; Chinen et al., 2006), morphine
(Vanderschuren et al., 2001; Valjent et al., 2010), ethanol
(Fukushiro et al., 2010) or nicotine (Frussa-Filho et al., un-
published observations) enhances locomotor stimulation
produced by a subsequent injection of the respective
drug given hours, days or weeks later. As shown by
Valjent et al. (2010), the two-injection protocol of behav-
ioural sensitization provides an excellent model for
investigating the long-lasting effects of drugs of abuse,
which is less inﬂuenced by some variables that add a
level of complexity in the interpretation of behavioural
responses resulting from the multiple drug exposure
protocols.
The main objective of the present study was to inves-
tigate the dose-dependent effects of neuroleptics of
the ﬁrst (haloperidol), second (ziprasidone) and third
(aripiprazole) generations in their capacity to selectively
inhibit the behavioural sensitization phenomenon at
doses that modify neither spontaneous locomotor activity
in a novel environment nor acute cocaine-induced
hyperlocomotion.
Method
Subjects
Male 3-month-old Swiss EPM-M2 mice (30–35 g) were
obtained from the Centre for Development of Experimen-
tal Models in Medicine and Biology of our institution
(Federal University of São Paulo –UNIFESP). Animals
were housed in polypropylene cages (32 cm×42 cm×
18 cm) under controlled temperature (22–23 °C) and light-
ing (12/12 h light/dark; lights on at 6:45 a.m.) conditions.
Food and water were available ad libitum throughout the
experiments. The experiments were performed in accord-
ance with the National Institute of Health Guide for the
care and use of laboratory animals (NIH Publications
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No 80-23, revised 1996), and animals were maintained in
accordance with the Brazilian Law for Procedures for An-
imal Scientiﬁc Use (#11794/2008). The experimental proce-
dures were approved by the Institutional Ethical
Committee of UNIFESP.
Drugs
Cocaine-HCl (Sigma®, Brazil), haloperidol (Janssen-
Cilag®, Brazil), ziprasidone (Pﬁzer®, Brazil) and aripipra-
zole (Bristol-Myers Squibb®, Brazil) were used. Cocaine
was diluted in saline. Haloperidol was dissolved in lactic
acid and diluted to the correct concentrations in distilled
water. Ziprasidone and aripiprazole were dissolved in
Tween 80 and diluted in saline. Solutions of saline, lactic
acid+distilled water and Tween 80+saline were used as
vehicles for cocaine, haloperidol and ziprasidone/
aripiprazole, respectively. All solutions were given intra-
peritoneally at the volume of 10ml/kg of body weight.
Open-ﬁeld evaluation
Locomotor activity was measured in the open ﬁeld ap-
paratus, as previously described by Chinen et al. (2006).
It consisted in a circular wooden arena (40 cm in diameter
and 50 cm high) with an open top and a ﬂoor divided into
19 squares. Hand-operated counters were used to score
the locomotion frequency (total number of any square
entered) during 10-min sessions by an observer, who
was blind to the treatment allocation. Ten-minute ses-
sions were proposed because it has been shown that
even shorter periods are effective in reliably evaluating
the effects of drugs acting on dopaminergic systems
(Frussa-Filho and Palermo-Neto, 1990; Vital et al., 1995;
Araujo et al., 2005; Castro et al., 2006), particularly
cocaine-induced stimulant effect and behavioural sensiti-
zation (Fukushiro et al., 2007, 2008).
Experimental procedure
For the ﬁrst experiment, 70 mice were allocated into ﬁve
groups that were acutely treated with either vehicle (V;
n=30) or haloperidol (H) at the doses of 0.01, 0.05, 0.10
and 0.25mg/kg (n=10 for each group) followed by initial
exposure to the open-ﬁeld environment 30min after treat-
ment to quantify their locomotor activities. The following
groups were compared in the ﬁrst open-ﬁeld exposure: V,
H 0.01, H 0.05, H 0.10 and H 0.25. Once removed from the
apparatus, 20 animals from the vehicle group received a
saline injection, and the remaining 10 mice were treated
with 10mg/kg cocaine (C). All animals pretreated with
haloperidol also received 10mg/kg cocaine. Five minutes
after administration of either saline or cocaine, the
animals were returned to the open-ﬁeld for locomotion
quantiﬁcation. Thus, the following groups were formed:
V-S, V-C, H 0.01-C, H 0.05-C, H 0.10-C and H 0.25-C.
Seven days later, 10 animals that were treated with
vehicle and saline on the previous week received saline
again (forming the V-S-S group) and the other 10 mice
were treated with 10mg/kg cocaine for the ﬁrst time
(forming the V-S-C group). Cocaine (10mg/kg) was also
administered to all the other animals for the second
time, forming the V-C-C, H 0.01-C-C, H 0.05-C-C, H
0.10-C-C and H 0.25-C-C groups. Five minutes after the
injections, mice were placed in the open-ﬁeld for loco-
motor activity quantiﬁcation. The experimental design
of expt 1 is summarized in Table 1.
Table 1. Design of expt 1
Groups Treatment 1 40 min Treatment 2 7 d Treatment
V-S-S VEH SAL SAL
V-S-C VEH SAL COC
V-C-C VEH COC COC
H 0.01-C-C HAL 0.01 COC COC
H 0.05-C-C HAL 0.05 COC COC
H 0.10-C-C HAL 0.10 COC COC
H 0.25-C-C HAL 0.25 COC COC
30 min
OFQ
5 min
OFQ
5 min
OFQ
VEH – vehicle, i.p. injection; HAL 0.01 – haloperidol 0.01mg/kg, i.p. injection; HAL 0.05 –
haloperidol 0.05mg/kg, i.p. injection; HAL 0.10 – haloperidol 0.10mg/kg, i.p. injection;
HAL 0.25 – haloperidol 0.25mg/kg, i.p. injection; COC – cocaine 10mg/kg, i.p. injection;
SAL – saline, i.p. injection; OFQ – open-ﬁeld locomotor activity quantiﬁcation for
10min. The same experimental design was used for expts 2 and 3, with the exception
that haloperidol was replaced with either ziprasidone (at the doses of 0.1, 0.5, 1.0 and
2.5mg/kg) or aripiprazole (at the doses of 0.1, 0.5, 1.0 and 2.5mg/kg), respectively.
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Expts 2 and 3 were performed following the protocol
for expt 1. Haloperidol was replaced with ziprasidone
at the doses of 0.1, 0.5, 1.0 or 2.5 mg/kg in the second ex-
periment and with aripiprazole at the doses of 0.1, 0.5, 1.0
or 2.5 mg/kg in the third experiment.
Statistical analysis
Before conducting the parametric tests, all variables were
checked for normality (Shapiro–Wilk test) and homogen-
eity (Levene’s test), which validated the use of the para-
metric test. Data were analysed by one-way analysis of
variance (ANOVA) followed by Tukey’s test for multiple
comparisons when necessary. A probability of p<0.05
was considered signiﬁcant.
Results
Experiment 1: effects of haloperidol on spontaneous
locomotor activity, acute cocaine-induced
hyperlocomotion and cocaine-induced behavioural
sensitization
In the ﬁrst behavioural evaluation (spontaneous loco-
motor activity in a novel environment), ANOVA revealed
signiﬁcant differences between groups [F(4,65)=6.75; p<
0.0001]. Haloperidol at the doses of 0.01 and 0.05mg/kg
did not modify spontaneous locomotor activity compared
with the vehicle group (Tukey’s test, p>0.05) (Fig. 1a). At
the doses of 0.10 and 0.25mg/kg, haloperidol led to a
signiﬁcant decrease in the locomotion frequency com-
pared with the vehicle group (Tukey’s test, p<0.05).
These data show that haloperidol signiﬁcantly reduces
spontaneous locomotor activity in a novel environment
at the doses of 0.10 and 0.25mg/kg, but not at lower
doses.
In the evaluation of acute cocaine-induced hyperloco-
motion after haloperidol treatment, statistically signiﬁ-
cant differences were observed between groups [F(5,64)
=11.54; p<0.0001]. An acute cocaine effect was observed
based on the signiﬁcantly higher locomotion frequency
in the vehicle–cocaine group compared with the
vehicle–saline group (Tukey’s test, p<0.01) as shown in
Fig. 1b. Haloperidol at the doses of 0.01 and 0.05mg/kg
did not affect cocaine-induced hyperlocomotion. How-
ever, at the doses of 0.10 and 0.25mg/kg, haloperidol
abolished the acute stimulating effect of cocaine (Tukey’s
test, p<0.05). These data indicate that haloperidol
abolishes acute cocaine-induced hyperlocomotion only
at doses that also reduce spontaneous locomotor activity
in a novel environment.
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Fig. 1. Locomotor activity quantiﬁcation in the open-ﬁeld
apparatus demonstrating the behavioural effects of i.p.
treatment with either haloperidol (0.01, 0.05, 0.10 or 0.25mg/
kg) or vehicle on (a) spontaneous locomotor activity in a novel
environment and its subsequent effects on (b) acute
cocaine-induced hyperlocomotion and (c) cocaine-induced
behavioural sensitization after a 7-d interval. Data are reported
as mean±S.E.M. *p<0.05 compared with vehicle (a), vehicle–
saline (b) or vehicle–saline–saline (c); •p<0.05 compared with
vehicle–cocaine (b) or vehicle–cocaine–cocaine (c); ○p<0.05
compared with vehicle–saline–cocaine (c). One-way analysis of
variance (ANOVA) followed by Tukey’s test.
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After 1 wk, cocaine-induced locomotor sensitization
was evaluated, and statistically signiﬁcant differences
were observed [F(6,63)=12.99; p<0.0001]. As shown in
Fig. 1c, an acute cocaine injection promoted an en-
hanced locomotion frequency (vehicle–saline–
cocaine>vehicle–saline–saline), which was potentiated in
the vehicle–cocaine–cocaine group (vehicle–cocaine–
cocaine>vehicle–saline–cocaine) (Tukey’s test, p<0.05),
indicating the development of behavioural sensitization.
Treatment with haloperidol at the doses of 0.01 and
0.05mg/kg before the ﬁrst cocaine administration did
not affect the cocaine-induced sensitization expressed
1wk later. However, pre-treatment with 0.10 and
0.25mg/kg haloperidol prevented the development of
behavioural sensitization, as shown by a signiﬁcant
decrease in the locomotor activity of these groups com-
pared with the vehicle–cocaine–cocaine group (Tukey’s
test, p<0.01). These data together indicate that haloperi-
dol prevents the induction of cocaine-induced behav-
ioural sensitization but only at doses that also inhibit
spontaneous locomotor activity in a novel environment
and acute cocaine-induced hyperlocomotion.
Experiment 2: effects of ziprasidone on spontaneous
locomotor activity, acute cocaine-induced
hyperlocomotion and cocaine-induced behavioural
sensitization
In the ﬁrst behavioural evaluation (spontaneous loco-
motor activity in a novel environment), ANOVA revealed
signiﬁcant differences between groups [F(4,65)=11.18; p<
0.0001]. Ziprasidone at the doses of 0.1 and 0.5 mg/kg did
not modify spontaneous locomotor activity compared
with the vehicle group (Tukey’s test, p>0.05) (Fig. 2a).
At the doses of 1.0 and 2.5mg/kg, ziprasidone led to a sig-
niﬁcant decrease in the locomotion frequency compared
with the vehicle group (Tukey’s test, p<0.01). These
data show that ziprasidone signiﬁcantly reduces spon-
taneous locomotor activity in a novel environment at
the doses of 1.0 and 2.5mg/kg, but not at lower doses.
In evaluating acute cocaine-induced hyperlocomotion
after ziprasidone treatment, statistically signiﬁcant differ-
ences were observed between groups [F(5,64)=10.86; p<
0.0001]. An acute cocaine effect was observed based on
the signiﬁcantly higher locomotion frequency presented
by the vehicle–cocaine group compared with the vehicle–
saline group (Tukey’s test, p<0.001) as shown in Fig. 2b.
Ziprasidone at the doses of 0.1 and 0.5 mg/kg did not af-
fect acute cocaine-induced hyperlocomotion. However, at
the doses of 1.0 and 2.5mg/kg, ziprasidone abolished the
acute stimulating effect of cocaine (Tukey’s test, p<0.001).
These data indicate that, like haloperidol, ziprasidone
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Fig. 2. Locomotor activity quantiﬁcation in the open-ﬁeld
apparatus demonstrating the effects of i.p. treatment with
either ziprasidone (0.1, 0.5, 1.0 or 2.5 mg/kg) or vehicle on
(a) spontaneous locomotor activity in a novel environment
and its subsequent effects on (b) acute cocaine-induced
hyperlocomotion and (c) cocaine-induced behavioural
sensitization after a 7-d interval. Data are reported as mean±
S.E.M. *p<0.05 compared with vehicle (a), vehicle–saline
(b) or vehicle–saline–saline (c); •p<0.05 compared with
vehicle–cocaine (b) or vehicle–cocaine–cocaine (c); ○p<0.05
compared to vehicle–saline–cocaine (c). One-way analysis of
variance (ANOVA) followed by Tukey’s test.
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abolishes acute cocaine-induced hyperlocomotion only at
doses that also reduce spontaneous locomotor activity in
a novel environment.
After 1 wk, cocaine-induced locomotor sensitization
was evaluated and statistically signiﬁcant differences
were observed [F(6,63)=9.03; p<0.0001]. As shown in
Fig. 2c, an acute cocaine injection promoted an enhanced
locomotion frequency (vehicle–saline–cocaine>vehicle–
saline–saline), which was potentiated in the vehicle–
cocaine–cocaine group (vehicle–cocaine–cocaine>
vehicle–saline–cocaine) (Tukey’s test, p<0.05), indicating
the development of behavioural sensitization. Treatment
with ziprasidone at all doses (0.1 to 2.5 mg/kg) before
the ﬁrst cocaine administration prevented the develop-
ment of behavioural sensitization, expressed 1wk later.
Indeed, the locomotor activity of groups pre-treated
with ziprasidone was signiﬁcantly lower than that
observed in the vehicle–cocaine–cocaine group (Tukey’s
test, p<0.05). These data together indicate that, unlike
haloperidol, low doses of ziprasidone selectively prevent
the development of cocaine-induced behavioural sensiti-
zation without modifying either spontaneous locomotor
activity in a novel environment or acute cocaine-induced
hyperlocomotion.
Experiment 3: effects of aripiprazole on spontaneous
locomotor activity, acute cocaine-induced
hyperlocomotion and cocaine-induced behavioural
sensitization
In the ﬁrst behavioural evaluation (spontaneous loco-
motor activity in a novel environment), ANOVA revealed
signiﬁcant differences between groups [F(4,65)=7.50; p<
0.0001]. Aripiprazole at the doses of 0.1 and 0.5 mg/kg
did not modify spontaneous locomotor activity compared
with the vehicle group (Tukey’s test, p>0.05) (Fig. 3a). At
the doses of 1.0 and 2.5mg/kg, aripiprazole led to a sign-
iﬁcant decrease in the locomotion frequency compared
with the vehicle group (Tukey’s test, p<0.01). These
data show that aripiprazole signiﬁcantly reduces spon-
taneous locomotor activity in a novel environment at
the doses of 1.0 and 2.5mg/kg, but not at lower doses.
In the evaluation of acute cocaine-induced hyperloco-
motion after aripiprazole treatment, statistically sig-
niﬁcant differences were observed between groups
[F(5,64)=38.25; p<0.0001]. An acute cocaine effect was ob-
served based on the signiﬁcantly higher locomotion fre-
quency in the vehicle–cocaine group compared with the
vehicle–saline group (Tukey’s test, p<0.001) as shown
in Fig. 3b. Aripiprazole at all doses (0.1 to 2.5 mg/kg)
abolished acute cocaine-induced hyperlocomotion
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Fig. 3. Locomotor activity quantiﬁcation in the open-ﬁeld
apparatus demonstrating the effects of i.p. treatment with
either aripiprazole (0.1, 0.5, 1.0 or 2.5 mg/kg) or vehicle on
(a) spontaneous locomotor activity in a novel environment and
its subsequent effects on (b) acute cocaine-induced
hyperlocomotion and (c) cocaine-induced behavioural
sensitization after a 7-d interval. Data are reported as mean±
S.E.M. *p<0.05 compared with vehicle (a), vehicle–saline
(b) or vehicle–saline–saline (c); •p<0.05 compared with vehicle–
cocaine (b) or vehicle–cocaine–cocaine (c); ○p<0.05 compared
with vehicle–saline–cocaine (c) group. One-way analysis of
variance (ANOVA) followed by Tukey’s test.
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(Tukey’s test, p<0.001). These data indicate that, unlike
haloperidol and ziprasidone, low doses of aripiprazole
prevent acute cocaine-induced hyperlocomotion without
modifying spontaneous locomotion in a novel
environment.
After 1 wk, cocaine-induced locomotor sensitization
was evaluated, and statistically signiﬁcant differences
were observed [F(6,63)=11.11; p<0.0001]. As shown in
Fig. 3c, an acute cocaine injection promoted an enhanced
locomotion frequency (vehicle–saline–cocaine> vehicle–
saline–saline), which was potentiated in the vehicle–
cocaine–cocaine group (vehicle–cocaine–cocaine>
vehicle–saline–cocaine) (Tukey’s test, p<0.001), indicating
the development of behavioural sensitization. Treatment
with aripiprazole at all doses (0.1 to 2.5mg/kg) before
the ﬁrst cocaine administration prevented the develop-
ment of behavioural sensitization, expressed 1wk later.
Indeed, the locomotor activity of the groups pre-treated
with aripiprazole was signiﬁcantly lower than that
observed in the vehicle–cocaine–cocaine group (Tukey’s
test, p<0.05). These data together indicate that, unlike
haloperidol and ziprasidone, low doses of aripiprazole
prevent both acute cocaine-induced hyperlocomotion
and the development of cocaine-induced behavioural sen-
sitization without modifying spontaneous locomotor
activity in a novel environment.
Discussion
The most important ﬁndings of the present study were
the following: (1) haloperidol had a non-speciﬁc effect
on cocaine-induced behavioural sensitization, acute
cocaine-induced hyperlocomotion and spontaneous loco-
motor activity in a novel environment, in that this drug
inhibited all of these behavioural phenomena at the
same doses; (2) ziprasidone showed higher sensitivity
in preventing the development of cocaine-induced behav-
ioural sensitization because it was attenuated by lower
doses than those required to reduce acute cocaine re-
sponse and spontaneous locomotion; (3) aripiprazole
was the only drug that showed selectivity to both acute
and sensitized cocaine responses in that it blocked these
phenomena at doses that did not change the spontaneous
locomotor activity in a novel environment.
The three antipsychotics used in the present study have
a common feature: they are either full or partial anta-
gonists at dopamine D2 receptors (Tadori et al., 2002),
blocking D2 autoreceptors as well as D2 post-synaptic
receptors. Antagonism at the autoreceptors increases do-
pamine function (Lidsky and Banerjee, 1993; Conceição
and Frussa-Filho, 1996; Frussa-Filho et al., 1997), which
is masked by the post-synaptic receptor antagonism
(Dias et al., 2012). Accordingly, at appropriate doses,
the three drugs reduced spontaneous locomotor behav-
iour, inhibited cocaine-induced hyperlocomotion and
blocked the development of cocaine-induced behavioural
sensitization, three phenomena that are all deeply related
to dopaminergic neurotransmission. Mesolimbicocortical
dopaminergic terminals are necessary for spontaneous
exploratory behaviour (Fink and Smith, 1980). Acutely
administered cocaine binds to the dopamine transporter
and inhibits its extracellular reuptake (Ritz et al., 1987),
prolonging the stimulation of dopamine D2 receptors by
the endogenous neurotransmitter, which results in in-
creased locomotor activity in rodents (Einhorn et al.,
1988; Ellinwood et al., 2000). Repeatedly stimulating
dopamine D2 autoreceptors leads to a marked sub-
sensitivity of these receptors (Henry et al., 1989, 1998;
Ackerman and White, 1990) and an increase in the basal
activity of dopamine neurons (Henry et al., 1998). These
neuroadaptations have been suggested to be related to
sensitized behaviour in mice (Kalivas and Stewart, 1991;
Henry et al., 1998; Brown et al., 2011), even in a two-
injection protocol (Keller et al., 1992). In this scenario,
the behavioural effects of haloperidol, ziprasidone and
aripiprazole were distinguished by their selectivity,
which can be explained by their different pharmaco-
dynamic features. For instance, haloperidol is a selective
antagonist at dopamine D2 receptors (Niemegeers,
1983); by blocking these receptors, it had a non-speciﬁc
effect: the inhibition of cocaine-induced hyperloco-
motion and the development of behavioural sensitization
only at doses that initially reduced spontaneous
locomotion.
Part of the non-speciﬁc effect observed after halo-
peridol treatment was also observed in ziprasidone treat-
ment. Ziprasidone inhibited acute cocaine effects only at
doses that also reduced spontaneous locomotor activity.
Nevertheless, unlike haloperidol, ziprasidone inhibited
the development of cocaine-induced behavioural sensiti-
zation at doses that did not affect either spontaneous
locomotor activity or acute cocaine-induced hyperloco-
motion. Unlike haloperidol, ziprasidone has a high
afﬁnity for both dopamine D2 and 5-HT receptors, acting
as a potent 5-HT2A receptor antagonist (Schmidt et al.,
2001). Within this context, there is extensive experimental
evidence demonstrating that in addition to dopaminergic
transmission, serotonergic transmission is necessary for
the development of cocaine-induced behavioural sensiti-
zation. It has been shown that repeated cocaine treatment
in mice simultaneously leads to an increase in the loco-
motor activity and in the cortical serotonin response
(Lanteri et al., 2008). Importantly, the repeated adminis-
tration of the 5-HT releaser p-chloroamphetamine re-
sulted in the development of behavioural sensitization
in mice (Itzhak et al., 2004). Additionally, some data
showed that behavioural sensitization to cocaine can be
prevented by the administration of the 5-HT2A receptor
antagonists ritanserin (Ago et al., 2006) and SR 46349B
(Salomon et al., 2006; Lanteri et al., 2008) during exposure
to this drug of abuse. Taken together, these ﬁndings are
in line with the higher selectivity of ziprasidone in
inhibiting cocaine-induced behavioural sensitization com-
pared with haloperidol.
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Aripiprazole was the most selective antipsychotic drug
concerning the inhibition of cocaine-induced behavioural
effects. It was more effective in blocking the acute effects
of cocaine than in attenuating spontaneous locomotion.
These results are in line with previous data showing
that aripiprazole is effective in preventing the increase
in locomotion induced by acute cocaine injection in
mice at doses that do not change basal motor activity
(Leite et al., 2008). This selectivity could be explained
by the fact that aripiprazole acts as a partial agonist at
dopamine D2 receptors (Burris et al., 2002), which
makes it a dopamine system stabilizer. Partial agonists
at D2 receptors selectively antagonize dopaminergic func-
tion resulting from high levels of synaptic dopamine
(Tadori et al., 2009). In addition, clinical studies have
been suggesting that antipsychotic medications such as
quetiapine and aripiprazole, which show less D2 antagon-
ism, appear to reduce substance use, whereas those that
exert more antagonistic effect at dopamine D2 receptors,
such as haloperidol, appear to have limited beneﬁts and
perhaps may increase the substance use, as mentioned be-
fore (Sattar et al., 2004; Kennedy et al., 2008; Martinotti
et al., 2008; Vorspan et al., 2008; Brunetti et al., 2012).
However, with regards to the control group, the spon-
taneous locomotor activity veriﬁed in a novel environ-
ment had the same magnitude as that observed after
acute cocaine administration in previously habituated
mice. These data indicate that synaptic levels of dopa-
mine were at the same magnitude during the recording
of the spontaneous locomotion in a novel environment
compared with acute cocaine-induced hyperlocomotion
after environmental habituation. Therefore, the partial
agonist activity of aripiprazole at the D2 receptor alone
does not explain the speciﬁcity of this drug for the block-
ade of acute cocaine-induced hyperlocomotion. Indeed,
the occupation of the dopamine transporter by selective
dopamine reuptake blockers does not lead to cocaine-like
behavioural proﬁles (Rothman et al., 1992; Newman et al.,
1994), indicating that an increase in the extracellular
dopamine concentrations might be a necessary but insufﬁ-
cient condition for the locomotor stimulant effects of this
drug. In this scenario, aripiprazole is also a known sero-
tonin system stabilizer with potent partial agonist activity
at serotonin 5HT1A receptors (Inoue et al., 1996; Jordan
et al., 2001). Selective drugs for the 5-HT1A receptor
have been found to modulate cocaine-induced locomotor
stimulation (Herges and Taylor, 1998; De La Garza and
Cunningham, 2000). Particularly, speciﬁc 5-HT1A receptor
antagonism inhibits the locomotor stimulant effect of co-
caine without inﬂuencing either locomotor baseline be-
haviour or dopamine release in the nucleus accumbens
(Carey et al., 2002; Müller et al., 2002a,b). Thus, the
speciﬁc action on serotonin 5HT1A receptors could ex-
plain the selectivity of aripiprazole in inhibiting acute co-
caine effects at doses that do not reduce spontaneous
locomotor activity. Importantly, aripiprazole also blocked
the development of behavioural sensitization to cocaine at
lower doses than those necessary for the inhibition of
spontaneous locomotor activity in a novel environment.
This was most likely attributable to its action as a sero-
tonin 5HT2A receptor antagonist (Burris et al., 2002;
Tadori et al., 2002), as was discussed for ziprasidone.
Although one must always be wary of extrapolating
clinical relevance from animal data, from a clinical
perspective haloperidol would not be the best choice for
preventive addiction therapies. Although it would be ef-
fective in inhibiting the mechanisms associated with the
development of addiction, this would occur only at
doses that per se would produce relevant and harmful
collateral effects on natural behaviours related to mesoac-
cumbens dopaminergic activation. This would not be the
case for ziprasidone because this drug blocked the devel-
opment of behavioural sensitization at doses that did not
affect either spontaneous locomotor activity or acute
cocaine-induced hyperlocomotion.
Aripiprazole, in its turn, would be expected to induce
the same inhibitory effect on the development of
addiction-related mechanisms, but always at the expense
of the loss of the acute cocaine stimulant effects. This
would be dangerous regarding addiction because aripi-
prazole could lead drug abusers to a state of overdose
in an acute relapse to the drug use by enhancing cocaine
consumption owing to its lack of effect. This hypothesis is
consistent with clinical data demonstrating that aripipra-
zole increases smoked cocaine self-administration in
humans (Haney et al., 2011). In this study, it was sug-
gested that aripiprazole increased self-administration to
compensate for a blunted subjective cocaine effect be-
cause it decreased the ratings of good drug effect and co-
caine quality following cocaine consumption. On the
other hand, to feel a blunted effect is not a rewarding
strategy, and after an acute relapse, this effect could
even prevent the drug use in the long term. Ziprasidone
blocked the development of behavioural sensitization at
doses that affected neither spontaneous locomotor ac-
tivity in a novel environment nor acute cocaine-induced
hyperlocomotion. Therefore, low doses of this antipsy-
chotic should be expected to impair the progress of addic-
tion mechanisms without attenuating the acute cocaine
stimulant effect, preventing overdose in acute relapse
events. However, in the long term, this therapeutic strat-
egy would not represent a cure for addiction because the
drug abuser might remain using the substance for long
periods, which could even represent a risk if the patient
quit the use of the medicine. In addition, it has been dem-
onstrated that ziprasidone might have an inﬂuence on the
QT interval in humans (Tan et al., 2009; Witsil et al.,
2012), and its use in cocaine abusers should have to be
monitored.
Together, the above-discussed considerations suggest
that aripiprazole would be the best choice for clinical pre-
ventive addiction therapies, providing relevant sugges-
tions to the clinical practice. This is consistent with
recent studies demonstrating that aripiprazole at lower
620 E. A. V. Marinho et al.
 by guest on June 3, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
(Martinotti et al., 2009), but not high (Kenna et al., 2009),
doses elicits a good response in decreasing drug use and
attenuating psychopathological symptom severity.
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